Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Fig. 4

Normalization (defined by a reduction of anti-dsDNA levels to <30 IU/mL) of anti-dsDNA levels and SRI-4 response. Data were assessed for significance for all patients with anti-dsDNA ≥30 IU/mL at baseline, irrespective of treatment assignment. dsDNA, double-stranded deoxyribonucleic acid; N, number of patients; SLE, systemic lupus erythematosus SRI-4, SLE Responder Index-4

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us